PSMA ADC - Progenics Pharmaceuticals
Alternative Names: Monomethylauristatin E-antiPSMA monoclonal antibody conjugate; PSMA Antibody Drug ConjugateLatest Information Update: 18 Dec 2023
At a glance
- Originator PSMA Development Company
- Developer Brown University; Progenics Pharmaceuticals; Rhode Island Hospital; University of Texas at Dallas
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glioblastoma; Prostate cancer